Beximco Pharmaceuticals (BXP) Trading Suspension Lifted on AIM After Audited Accounts Published

Trading in Beximco Pharmaceuticals GDRs Resumes on AIM from 26 June 2026

The formal notice confirmed that trading in Beximco Pharmaceuticals PLC's Global Depositary Receipts on AIM was restored at 7:30am on 26 June 2026. The lifting of the suspension follows the company satisfying the condition cited at the time the suspension was imposed — namely, the publication of its annual audited accounts. AIM-quoted companies are required to publish audited annual results within prescribed timeframes, and a failure or delay in doing so can result in a temporary Trading halt imposed by the London Stock Exchange.

The restoration means that Market Participants — including institutional and retail investors — who hold or wish to acquire BXP GDRs will once again be able to execute transactions through normal AIM market mechanisms. During a period of suspension, price discovery is effectively frozen and Liquidity is unavailable, which can create significant uncertainty for investors. The resumption of trading brings an end to that period of enforced illiquidity for BXP holders.

The Role of Annual Audited Accounts in the AIM Suspension and Restoration Process

Under AIM Rules for Companies, businesses whose securities are admitted to trading on AIM are obliged to publish annual audited financial statements within a set timeframe following their financial year end. Where a company fails to meet this deadline, the London Stock Exchange has the power to temporarily suspend trading in that company's securities until the obligation is fulfilled. The suspension is intended to protect investors by ensuring that material financial information is publicly available before trading can continue.

In Beximco Pharmaceuticals' case, the announcement states explicitly that the suspension has been lifted because the annual audited accounts have now been published. This confirms that the company has met the relevant AIM reporting obligation. The content and findings of those audited accounts — including any audit opinion, financial results, or commentary from management — are contained within the accounts themselves, and investors and analysts will likely scrutinise that document closely now that trading has resumed.

Beximco Pharmaceuticals' GDR Structure and AIM Listing Details

Beximco Pharmaceuticals PLC is listed on AIM through Global Depositary Receipts rather than ordinary shares directly. Each GDR represents one ordinary share of BDT10 (Bangladeshi taka) in the underlying company, with the GDRs described as fully paid. The securities are identified by ISIN US0885792061 and SEDOL code B0DM5S5. This GDR structure is a common mechanism used by companies incorporated outside the United Kingdom — including in South Asia — to access international Capital-markets/">Capital Markets and provide foreign investors with a more straightforward route to gaining exposure to the underlying Equity.

Beximco Pharmaceuticals is one of Bangladesh's largest and most prominent pharmaceutical manufacturers, with operations spanning the production and export of generic medicines. The company's AIM listing via GDRs has historically allowed international investors to participate in the growth of Bangladesh's pharmaceutical sector. The fact that the securities are denominated in GDR form, with an underlying share denomination in Bangladeshi taka, means that investors are also exposed to currency dynamics between sterling or other Investment currencies and the BDT.

What the Restoration Notice Does and Does Not Confirm

The restoration announcement, as published via RNS, is a procedural notice confirming the administrative lifting of the trading suspension. It confirms two facts: that a suspension was previously in place, and that it has now been lifted following the publication of annual audited accounts. The notice does not contain any financial results, Revenue figures, profit or loss data, Dividend declarations, or forward guidance. Accordingly, the financial performance of Beximco Pharmaceuticals for the period covered by those accounts is not disclosed within this particular announcement.

Investors seeking details of the company's financial position, trading performance, or auditor's opinion will need to refer directly to the annual audited accounts that have been published separately. The company did not disclose this figure in the announcement, nor did it provide any commentary on the financial content of those accounts within the restoration notice itself. This is consistent with the nature of a restoration notice, which is a market-administrative document rather than a results announcement.

Nominated Adviser Contact and Regulatory Oversight of BXP on AIM

The restoration notice directs any queries to the company's nominated adviser (Nomad), providing contact numbers of +44 (0)20 3368 3551 and +44 (0)20 3368 3555. Under AIM Rules, every AIM-quoted company is required to retain a Nomad at all times. The Nomad plays a central role in ensuring the company's compliance with AIM Rules, guiding the company through regulatory obligations and acting as a key point of contact for the London Stock Exchange. The inclusion of the Nomad's contact details in the restoration notice is standard practice.

The Nomad's involvement in the restoration process is significant because it is the Nomad's responsibility to confirm to the London Stock Exchange that the company has satisfied the conditions necessary for trading to resume. In this instance, the publication of the annual audited accounts appears to have fulfilled that requirement. Investors with detailed regulatory queries about the nature or duration of the suspension, or about the accounts themselves, are directed by the announcement to contact the Nomad directly.

Implications for BXP Investors Following the Return to Active Trading

For investors who held BXP GDRs during the suspension period, the restoration of trading represents a material change in their ability to manage their positions. During a suspension, the inability to buy or sell can prevent investors from responding to new information or adjusting their portfolios in line with changing circumstances. With trading now restored, normal market activity — including price discovery and the ability to transact — resumes. The immediate share price impact was not clear from available public information at the time the restoration notice was published.

The period immediately following a restoration of trading on AIM can sometimes be characterised by elevated Volatility as the market absorbs the information contained in the previously unavailable annual accounts and resets pricing accordingly. Investors may be watching closely to see whether the audited accounts contain any material developments — whether positive or negative — that were not previously known or anticipated. Any analyst commentary, institutional investor activity, or further corporate announcements in the near term may also influence how the market responds to the resumption of trading.

Background on AIM Trading Suspensions and How They Are Resolved

Trading suspensions on AIM, whilst not uncommon, are typically viewed as a regulatory mechanism of last resort applied when a company has failed to meet a time-critical disclosure obligation. The most frequent cause of such suspensions is the late publication of annual audited accounts, though suspensions can also arise in connection with reverse takeovers, significant transactions, or pending material announcements. In each case, the purpose is to prevent trading from occurring in an information vacuum that could disadvantage investors.

The resolution process generally requires the company and its Nomad to work together to satisfy the outstanding obligation — in this case, completing and publishing the audit — before applying to the London Stock Exchange for the suspension to be lifted. Once the exchange is satisfied that the relevant condition has been met, a formal restoration notice is issued via RNS, as was the case with Beximco Pharmaceuticals on 26 June 2026. The speed with which a company resolves the underlying cause of a suspension can itself be informative, though the specific timeline of events in this instance was not detailed in the restoration notice.

Beximco Pharmaceuticals' Position Within Bangladesh's Pharmaceutical Industry

Beximco Pharmaceuticals operates within one of Bangladesh's most strategically important industrial sectors. Bangladesh's pharmaceutical industry has grown substantially over recent decades, transitioning from a primarily Import-dependent market to one that is now largely self-sufficient in generic medicines, and which exports to a growing number of international markets. Beximco Pharmaceuticals has been a significant participant in that development, and its international capital market presence through the AIM listing reflects the company's ambitions to attract global investment.

The company's dual exposure — to both the domestic Bangladeshi market and international export channels — means that investors in the GDRs must consider a range of factors including regulatory approvals in export markets, currency risk associated with the Bangladeshi taka, and the broader macroeconomic environment in Bangladesh. None of these matters were addressed in the restoration notice itself, which was confined strictly to the administrative confirmation of the lifting of the trading suspension. Investors will need to assess the annual audited accounts for any updated information on these dimensions of the Business.

Next Steps for Investors Monitoring BXP Following the Suspension Lift

With trading now restored, the most immediate priority for investors and analysts will be to review the content of the annual audited accounts that triggered the lifting of the suspension. These accounts will contain the company's full-year financial statements, notes to the accounts, and the independent auditor's report — all of which will be essential reading for anyone seeking to form a view on the company's financial health and prospects. The announcement did not indicate where or how investors could access the accounts directly, beyond confirming that they had been published.

Investors may also be watching for any further regulatory announcements or corporate updates from Beximco Pharmaceuticals in the near term, particularly given that the suspension period may have seen a build-up of news flow or developments that require disclosure. Any new announcements — whether in relation to trading performance, corporate activity, or changes in the company's regulatory status — would be expected to be released via RNS in accordance with the company's AIM disclosure obligations. Queries may continue to be directed to the nominated adviser at the contact numbers provided in the restoration notice.